Chapter 2 28 References 1. J. Steffel, P. Verhamme, T.S. Potpara, et al., The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation, Eur. Heart J. 39 (16) (2018) 1330–1393. 2. P. Kirchhof, S. Benussi, D. Kotecha, et al., 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur. Heart J. 37 (38) (2016) 2893–2962. 3. G. Flaker, R.D. Lopes, S.M. Al-Khatib, et al., Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation), J. Am. Coll. Cardiol. 63 (11) (2014) 1082–1087. 4. R. Nagarakanti, M.D. Ezekowitz, J. Oldgren, et al., Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion, Circulation. 123 (2) (2011) 131–136. 5. J.P. Piccini, S.R. Stevens, Y. Lokhnygina, et al., Outcomes after cardioversion and atrial fibrillation ablation in patients treatedwith rivaroxaban andwarfarin in the ROCKET AF trial, J. Am. Coll. Cardiol. 61 (19) (2013) 1998–2006. 6. A. Plitt, M.D. Ezekowitz, R. De Caterina, et al., Cardioversion of atrial fibrillation in ENGAGE AFTIMI 48, Clin. Cardiol. 39 (6) (2016) 345–346. 7. R. Cappato, M.D. Ezekowitz, A.L. Klein, et al., Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation, Eur. Heart J. 35 (47) (2014) 3346–3355. 8. M.D. Ezekowitz, C.V. Pollack Jr., J.L. Halperin, et al., Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial, Eur. Heart J. 39 (32) (2018) 2959–2971. 9. A. Goette, J.L. Merino, M.D. Ezekowitz, et al., Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial, Lancet. 388 (10055) (2016) 1995–2003. 10. S. Itainen, M. Lehto, T. Vasankari, et al., Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion, Europace. 20 (4) (2018) 565–568. 11. A.S. Frederiksen, A.E. Albertsen, A.M.S. Christesen, N. Vinter, L. Frost, D.S. Moller, Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin, Europace. 20 (7) (2018) 1078–1085. 12. G. Femia, T. Fetahovic, P. Shetty, A. Lee, Novel Oral anticoagulants in direct current Cardioversion for atrial fibrillation, Heart Lung Circ. 27 (7) (2018) 798–803. 13. A.K. Johansson, T. Juhlin, J. Engdahl, et al., Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism? Europace. 17 (10) (2015) 1514–1517. 14. R.M. Kaplan, C.L. Diaz, T. Strzelczyk, et al., Outcomes with novel Oral anticoagulants in obese patients who underwent electrical Cardioversion for atrial Tachyarrhythmias, Am. J. Cardiol. 122 (7) (2018) 1175–1178. 15. S. Itainen-Stromberg, A.M. Hekkala, A.L. Aro, T. Vasankari, K.E.J. Airaksinen,M. Lehto, Real-life experience with non-vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation, Ann. Noninvasive Electrocardiol. 25 (2020) (e12766). 16. N. Shibata, I.Morishima, K. Okumura, et al., Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: a single-center experience, J. Arrhythm. 33 (1) (2017) 7–11. 17. C.M. Coleman, S. Khalaf, S.Mould, et al., Novel Oral anticoagulants for DC Cardioversion procedures: utilization and clinical outcomes compared with warfarin, Pacing Clin. Electrophysiol. 38 (6) (2015) 731–737. 18. S. Kochhauser, Y. Khaykin, J. Beardsall, et al., Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens, Can. J. Cardiol. 30 (12) (2014) 1541–1546. 19. S. Schulman, C. Kearon, Subcommittee on control of anticoagulation of the S, standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical
RkJQdWJsaXNoZXIy MTk4NDMw